文献速递临床试验与 GCP真实世界研究与卫生经济

在印度新德里对孤独症谱系障碍幼儿开展PASS Plus干预的临床与成本效果随机对照试验:COMPASS试验研究方案

A randomised controlled trial of clinical and cost-effectiveness of the PASS Plus intervention for young children with autism spectrum disorder in New Delhi, India: study protocol for the COMPASS trial.
PubMed 文献 · Trials · 2023-10-12

COMPASS试验是一项在印度新德里两所三级政府医院开展的两中心、双臂、单(评估者)盲随机平行组研究,比较PASS Plus干预联合常规治疗与单独常规治疗对2至9岁孤独症谱系障碍儿童的临床与成本效果。计划招募240名儿童(约120名干预组/120名常规治疗组),主要终点为随机化后9个月的孤独症症状严重程度,随访至15个月。

要点

  • PASS Plus是在南亚为非专业社区人员系统改编的家长介导社交沟通干预,前期随机对照试验显示可行、可接受且对亲子二元结局有积极效果。
  • 本研究计划招募240名2至9岁孤独症谱系障碍儿童,从印度新德里两所三级政府医院招募,按约120名干预组/120名常规治疗组随机分配。
  • 主要终点为随机化后9个月的孤独症症状严重程度,随访至15个月,主要分析采用意向性治疗原则和线性混合模型回归。

核心结论

  • 若PASS Plus干预具有临床与成本效果,该方案将填补低资源背景下由非专业卫生工作者在现有照护路径中提供可扩展干预的重要空白。
  • 该方案在COVID-19大流行及限制措施期间实施,干预实施与评估流程已针对这些条件进行调整。

研究设计与样本

  • COMPASS试验为两中心、双臂、单(评估者)盲随机分配平行组研究,比较PASS Plus干预联合常规治疗与单独常规治疗,并嵌入印度卫生系统的卫生经济学评价。
  • 计划从印度新德里两所三级政府医院招募240名2至9岁孤独症谱系障碍儿童,约120名干预组/120名常规治疗组。
  • 认可的社区卫生活动家(Accredited Social Health Activists)将作为干预实施者之一。
  • 家庭将在8个月内完成最多12次沟通课程,并获得针对共存问题的Plus模块。
  • 主要终点为随机化后9个月,随访至15个月;主要分析采用意向性治疗原则,使用线性混合模型回归,以分组分配和重复测量为随机效应;成本效果分析采用社会视角,覆盖15个月干预期和随访期。

主要发现

  • PASS和PASS Plus的随机对照试验均显示可行性、可接受性及对家长和儿童二元结局的积极效果。
  • 主要结局为孤独症症状严重程度;次要结局包括亲子沟通、儿童适应、生活质量和父母幸福感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autism Spectrum Disorder (ASD) is a neurodevelopmental disability affecting at least 5 million children in South Asia. Majority of these children are without access to evidence-based care. The UK Pre-school Autism Communication Therapy (PACT) is the only intervention to have shown sustained impact on autism symptoms. It was systematically adapted for non-specialist community delivery in South Asia, as the 'Parent-mediated Autism Social Communication Intervention for non-Specialists (PASS)' and extended 'PASS Plus' interventions. RCTs of both showed feasibility, acceptability and positive effect on parent and child dyadic outcomes. METHODS: The Communication-centred Parent-mediated treatment for Autism Spectrum Disorder in South Asia (COMPASS) trial is now a scale-up two-centre, two-arm single (rater) blinded random allocation parallel group study of the PASS Plus intervention in addition to treatment as usual (TAU) compared to TAU alone, plus health economic evaluation embedded in the India health system. Two hundred forty children (approximately 120 intervention/120 TAU) with ASD aged 2-9 years will be recruited from two tertiary care government hospitals in New Delhi, India. Accredited Social Health Activists will be one of the intervention delivery agents. Families will undertake up to 12 communication sessions over 8 months and will be offered the Plus modules which address coexisting problems. The trial's primary endpoint is at 9 months from randomisation, with follow-up at 15 months. The primary outcome is autism symptom severity; secondary outcomes include parent-child communication, child adaptation, quality of life and parental wellbeing. Primary analysis will follow intention-to-treat principles using linear mixed model regressions with group allocation and repeated measures as random effects. The cost-effectiveness analysis will use a societal perspective over the 15-month period of intervention and follow-up. DISCUSSION: If clinically and cost-effective, this programme will fill an important gap of scalable interventions delivered by non-specialist health workers within the current care pathways for autistic children and their families in low-resource contexts. The programme has been implemented through the COVID-19 pandemic when restrictions were in place; intervention delivery and evaluation processes have been adapted to address these conditions. TRIAL REGISTRATION: ISRCTN; ISRCTN21454676 ; Registered 22 June 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Roy R, Leadbitter K, Shields G, et al. A randomised controlled trial of clinical and cost-effectiveness of the PASS Plus intervention for young children with autism spectrum disorder in New Delhi, India: study protocol for the COMPASS trial. Trials. 2023. PMID: 37828540. doi:10.1186/s13063-023-07621-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。